These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 10786681

  • 1. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N.
    Cancer Res; 2000 Apr 15; 60(8):2169-77. PubMed ID: 10786681
    [Abstract] [Full Text] [Related]

  • 2. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
    Shiose S, Sakamoto T, Yoshikawa H, Hata Y, Kawano Y, Ishibashi T, Inomata H, Takayama K, Ueno H.
    Invest Ophthalmol Vis Sci; 2000 Aug 15; 41(9):2395-403. PubMed ID: 10937546
    [Abstract] [Full Text] [Related]

  • 3. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H, Eto M, Ueno H, Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S.
    Oncol Rep; 2006 May 15; 15(5):1333-7. PubMed ID: 16596207
    [Abstract] [Full Text] [Related]

  • 4. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.
    Clin Cancer Res; 2000 Mar 15; 6(3):957-65. PubMed ID: 10741721
    [Abstract] [Full Text] [Related]

  • 5. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 6. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration.
    Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H.
    Gene Ther; 2000 Jun 15; 7(11):978-85. PubMed ID: 10849558
    [Abstract] [Full Text] [Related]

  • 7. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
    Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De Rosa G, Salvatore G, Fusco A, Persico MG, Viglietto G.
    Oncogene; 1999 Aug 26; 18(34):4860-9. PubMed ID: 10490819
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 9. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S.
    Princess Takamatsu Symp; 1994 Aug 01; 24():162-70. PubMed ID: 8983073
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D.
    Cancer Res; 1996 Mar 15; 56(6):1324-30. PubMed ID: 8640821
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM.
    Medicina (B Aires); 2000 Mar 15; 60 Suppl 2():41-7. PubMed ID: 11188930
    [Abstract] [Full Text] [Related]

  • 12. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marmé D, Martiny-Baron G.
    Cancer Res; 1999 Jul 01; 59(13):3185-91. PubMed ID: 10397264
    [Abstract] [Full Text] [Related]

  • 13. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis.
    Sakamoto T, Ueno H, Sonoda K, Hisatomi T, Shimizu K, Ohashi H, Inomata H.
    Gene Ther; 2000 Nov 01; 7(22):1915-24. PubMed ID: 11127579
    [Abstract] [Full Text] [Related]

  • 14. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Huber J, Nakatani T, Tsujinoue H, Yanase K, Imazu H, Fukui H.
    Hepatology; 2002 Apr 01; 35(4):834-42. PubMed ID: 11915029
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
    Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, Sonnabend JA, Pintus A, Gallo RC, Ensoli B.
    Am J Pathol; 1998 Jun 01; 152(6):1433-43. PubMed ID: 9626048
    [Abstract] [Full Text] [Related]

  • 16. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
    Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G.
    J Clin Invest; 2002 Mar 01; 109(6):777-85. PubMed ID: 11901186
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
    Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG.
    Cell Growth Differ; 1998 Jan 01; 9(1):49-58. PubMed ID: 9438388
    [Abstract] [Full Text] [Related]

  • 18. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo.
    Riccioni T, Cirielli C, Wang X, Passaniti A, Capogrossi MC.
    Gene Ther; 1998 Jun 01; 5(6):747-54. PubMed ID: 9747454
    [Abstract] [Full Text] [Related]

  • 19. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 20. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H.
    Hepatology; 1999 Nov 01; 30(5):1179-86. PubMed ID: 10534339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.